# Boreal Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/boreal-genomics

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.borealgenomics.com
- Total disclosed funding: $25M
- Latest round: Series C (Oct 5, 2013)
- Investors on record: 4

## About

Boreal Genomics, Inc. is a biotechnology company specializing in advanced genomic solutions. They focus on providing innovative technologies to enhance genetic research and applications across various sectors.Boreal Genomics, Inc. operates in the biotechnology sector, focusing on genomic solutions. The company is headquartered in Vancouver, Canada. Founded by Andre Marziali, Boreal Genomics was established to leverage advancements in genomic science. In October 2013, the company raised USD 18 mn in Series C funding from ARCH Venture Partners, Kearny Venture Partners, and other investors, bringing the total amount raised to USD 18 mn. The company has been involved in two significant investment deals, with the latest deal occurring on October 5, 2013.Boreal Genomics specializes in innovative genomic solutions aimed at enhancing genetic research and applications. Their offerings include proprietary platforms designed to streamline genomic data analysis and improve the accuracy of genetic testing, catering to a wide range of clients from research institutions to healthcare providers. The company focuses on delivering solutions that address challenges in genomic research, aiming to facilitate advancements in personalized medicine and diagnostics.Boreal Genomics generates revenue primarily through its genomic solution offerings, which are often utilized by research institutions and healthcare organizations on a subscription basis. Clients engage in recurring transactions, ensuring access to the latest genomic technologies and support services. The structured pricing models allow clients to choose plans that suit their specific needs, fostering long-term partnerships and client retention across various sectors.Boreal Genomics plans to enhance its product portfolio with upcoming launches of advanced genomic analysis tools aimed at improving data processing efficiency. The company is targeting expansion into North American and European markets by 2015, leveraging the recent USD 18 mn from its Series C funding to support these initiatives. This funding will facilitate the development of new products and enhance marketing efforts to penetrate these key regions.

## Funding rounds

- Series C, Oct 5, 2013, $18M — ARCH Venture Partners, Kearny Venture Partners
- Series B, Dec 15, 2010, $6.9M — ARCH Venture Partners, GrowthWorks Capital, Kearny Venture Partners, In-Q-Tel

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B, Series C
- GrowthWorks Capital (https://capitalatlas.ai/funds/growthworks-capital) — Series B
- Kearny Venture Partners (https://capitalatlas.ai/funds/kearny-venture-partners) — Series B, Series C
- In-Q-Tel (https://capitalatlas.ai/funds/in-q-tel) — Series B